Jove
Visualize
Contact Us

Related Experiment Videos

Antisense imaging: where are we now?

D J Hnatowich1

  • 1Department of Radiology, University of Massachusetts Medical School, Worcester, MA 01655, USA. donald.hnatowich@umass med.edu

Cancer Biotherapy & Radiopharmaceuticals
|January 13, 2001
PubMed
Summary

Antisense imaging can be reconsidered due to rapid advancements in antisense targeting, including chemotherapy, radiotherapy, and DNA radiolabeling. New insights may refine antisense imaging mechanisms and carrier influences for improved targeting and tissue counting.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.

The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...·2010
Same author

[Preparation and quality control of 99mTc labeled MDR1 oligonucleotide DNAs].

Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi·2008
Same author

Cell studies of a three-component antisense MORF/tat/Herceptin nanoparticle designed for improved tumor delivery.

Cancer gene therapy·2007
Same author

[Experimental study of 99mTc-antisense DNA for tumor imaging].

Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi·2007
Same author

Evidence of antisense tumor targeting in mice.

Bioconjugate chemistry·2004
Same author

Investigations of 99mTc morpholino pretargeting in mice.

Nuclear medicine communications·2003
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Medical Imaging

Background:

  • Antisense targeting is evolving rapidly with new in vitro, animal, and patient trial data.
  • Developments in antisense chemotherapy have potential implications for antisense imaging and radiotherapy.

Purpose of the Study:

  • To re-evaluate the potential of antisense imaging in light of recent advancements.
  • To predict optimal antisense mechanisms for imaging.
  • To explore the impact of carriers (vectors) on antisense DNA targeting for imaging.

Main Methods:

  • Review of recent in vitro studies, animal, and patient trial data.
  • Analysis of antisense targeting mechanisms and their suitability for imaging.
  • Consideration of carrier (vector) effects on DNA targeting.
  • Re-evaluation of mRNA steady-state copy numbers per cell.
  • Assessment of radiolabeling effects on antisense DNA targeting properties.

Main Results:

  • Recent developments suggest a renewed profitability in antisense imaging.
  • New insights may allow prediction of preferable antisense mechanisms for imaging.
  • Carrier (vector) influences on antisense DNA targeting for imaging can be explored.
  • Low mRNA copy number estimates may require reconsideration for tissue counting rates.
  • Radiolabeling of antisense DNAs appears not to adversely affect their targeting properties.

Conclusions:

  • Antisense imaging warrants reconsideration due to rapid progress in the field.
  • Further research into antisense mechanisms, carriers, and radiolabeling can optimize antisense imaging.
  • Accurate predictions of tissue counting rates may be refined with updated mRNA estimates.

Related Experiment Videos